Aspirin treatment improved mesenchymal stem cell immunomodulatory properties via the 15d-PGJ2/PPARγ/TGF-β1 pathway

Stem Cells and Development

Volumn 23, Issue 17, 2014, Pages 2093-2103

  Tang, Jianxia ^a,b   Xiong, Jimin ^a   Wu, Tingting ^a   Tang, Zhangui ^b   Ding, Gang ^c   Zhang, Chunmei ^a   Wang, Songlin ^a   Liu, Yi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

15D PROSTAGLANDIN J2; ACETYLSALICYLIC ACID; DEXTRAN SULFATE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROSTAGLANDIN J2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 15-DEOXYPROSTAGLANDIN J2; PROSTAGLANDIN D2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFECT; EXPERIMENTAL COLITIS; FEMALE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SPLEEN CELL; TH17 CELL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL CULTURE; COCULTURE; COLITIS; DRUG EFFECTS; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; ASPIRIN; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; COLITIS; DINOPROSTONE; FEMALE; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; PPAR GAMMA; PROSTAGLANDIN D2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84906537462     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0081     Document Type: Article

References (37)

1. Campagnoli C, IA Roberts, S Kumar, PR Bennett, I Bellantuono and NM Fisk. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver and bone marrow. Blood 98:2396-2402.
2. Seo BM, M Miura, S Gronthos, PM Bartold, S Batouli, J Brahim, M Young, PG Robey, CY Wang and S Shi. (2004). Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet 364:149-155.
3. Bianco P, PG Robey and PJ Simmons. (2008). Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2:313-319.
4. Liu Y, S Wang and S Shi. (2012). The role of recipient cells in mesenchymal stem cell-based tissue regeneration. Int J Biochem Cell Biol 44:2044-2050.
5. Shi Y, J Su, AI Roberts, P Shou, AB Rabson and G Ren. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 33:136-143.
6. Le Blanc K, I Rasmusson, B Sundberg, C Götherström, M Hassan, M Uzunel and O Ringdén. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
7. Sun L, K Akiyama, H Zhang, T Yamaza, Y Hou, S Zhao, T Xu, A Le and S Shi. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432.
8. Zhou B, J Yuan, Y Zhou, M Jr Ghawji, YP Deng, AJ Lee, AJ Lee, U Nair, AH Kang, DD Brand and TJ Yoo. (2011). Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. Clin Immunol 141:328-337.
9. Dalal J, K Gandy and J Domen. (2012). Role of mesenchymal stem cell therapy in Crohn's disease. Pediatr Res 71:445-451.
10. Xu J, D Wang, D Liu, Z Fan, H Zhang, O Liu, G Ding, R Gao, C Zhang, et al. (2012). Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood 120:3142-3151.
11. Akiyama K, C Chen, D Wang, X Xu, C Qu, T Yamata, T Cai, W Chen, L Sun and S Shi. (2012). Mesenchymalstem- cell-induced immunoregulation involves FAS-ligand-/ FAS-mediated T cell apoptosis. Cell Stem Cell 10:544-555.
12. Liu D, J Xu, O Liu, Z Fan, Y Liu, F Wang, G Ding, F Wei, C Zhang and S Wang. (2012). Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation. J Clin Periodontol 39:1174-1182.
13. Wang L, Y Zhao, Y Liu, K Akiyama, C Chen, C Qu, Y Jin and S Shi. (2013). IFN-g and TNF-a synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFkB signaling. Stem Cells 31:1383-1395.
14. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, RC Zhao and Y Shi. (2008). Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141-150.
15. Sudres M, F Norol, A Trenado, S Grégoire, F Charlotte, B Levacher, JJ Lataillade, P Bourin, X Holy, et al. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versushost disease in mice. J Immunol 176:7761-7767.
16. Papadopoulou A, M Yiangou, E Athanasiou, N Zogas, P Kaloyannidis, I Batsis, A Fassas, A Anagnostopoulos and E Yannaki. (2012). Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis 71:1733-1740.
17. Wu CC, TC Wu, FL Liu, HK Sytwu and DM Chang. (2012). TNF-a inhibitor reverse the effects of human umbilical cord-derived stem cells on experimental arthritis by increasing immunosuppression. Cell Immunol 273:30-40.
18. Mangi AA, N Noiseux, D Kong, H He, M Rezvani, JS Ingwall and VJ Dzau. (2003). Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9:1195-1201.
19. Park MJ, HS Park, ML Cho, HJ Oh, YG Cho, SY Min, BH Chung, JW Lee, HY Kim and SG Cho. (2011). Transforming growth factor b-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17cells and osteoclastogenesis. Arthritis Rheum 63:1668-1680.
20. Muller DN, V Heissmeyer, R Dechend, F Hampich, JK Park, A Fiebeler, E Shagdarsuren, J Theuer, M Elger, et al. (2001). Aspirin inhibits NF-kappa Band protects from angiotensin II-induced organ damage. FASEB J 15:1822-1824.
21. Kwon MS, EJ Shim, YJ Seo, SS Choi, JY Lee, HK Lee and HW Suh. (2005). Effect of aspirin and acetaminophen on proinflammatory cytokine-induced pain behavior in mice. Pharmacology 74:152-156.
22. Tosco P and L Lazzarato. (2009). Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. Chem Med Chem 4:939-945.
23. Liu Y, L Wang, T Kikuiri, K Akiyama, C Chen, X Xu, R Yang, W Chen, S Wang and S Shi. (2011). Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 17:1594-1601.
24. Matasic R, AB Dietz and S Vuk-Pavlovic. (2000). Cyclooxygenase- independent inhibition of dendritic cell maturation by aspirin. Immunology 101:53-60.
25. Hackstein H, AE Morelli, AT Larregina, RW Ganster, GD Papworth, AJ Logar, SC Watkins, LD Falo and AW Thomson. (2001). Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 166:7053-7062.
26. Yang R, Y Liu, P Kelk, C Qu, K Akiyama, C Chen, I Atsuta, W Chen, Y Zhou and S Shi. (2012). A subset of IL-17 + mesenchymal stem cells possesses anti-Candida albicans effect. Cell Res 23:107-121.
27. Alex P, NC Zachos, T Nguyen, L Gonzales, TE Chen, LS Conklin, M Centola and X Li. (2009). Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-Induced colitis. Inflamm Bowel Dis 15: 341-352.
28. Lee SJ, EK Yang and SG Kim. (2006). Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTENmediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 70:415-425.
29. Madec AM, R Mallone, G Afonso, E Abou Mrad, A Mesnier, A Eljaafari and C Thivolet. (2009). Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52:1391-1399.
30. Wang Y, X Chen, W Zhu, H Zhang, S Hu and X Cong. (2006). Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol 33:696-701.
31. Deng L, S Hu, AR Baydoun, J Chen, X Chen and X Cong. (2009). Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway. Cell Prolif 42: 721-730.
32. Chen C, K Akiyama, T Yamaza, YO You, X Xu, B Li, Y Zhao and S Shi. (2014).Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression. EMBO Mol Med 6:322-334.
33. Carbone LD, FA Tylavsky, JA Cauley, TB Harris, TF Lang, DC Bauer, KD Barrow and SB Kritchevsky. (2003). Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18:1795-1802.
34. Yamaza T, Y Miura, Y Bi, Y Liu, K Akiyama,WSonoyama, V Patel, S Gutkind, M Young, et al. (2008). Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 3:e2615.
35. Sato K, K Ozaki, I Oh, A Meguro, K Hatanaka, T Nagai, K Muroi and K Ozawa. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228-234.
36. Hsu WT, CH Lin, BL Chiang, HY Jui, KK Wu and CM Lee. (2013). Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10 + IFN-g+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol 190:2372-2380.
37. Shen W, Y Li, J Zhu, R Schwendener and J Huard. (2008). Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. J Cell Physiol 214:405-412.